VanEck Pharmaceutical ETF
PPH
136 hedge funds and large institutions have $531M invested in VanEck Pharmaceutical ETF in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 50 reducing their positions, and 25 closing their positions.
3% more capital invested
Capital invested by funds: $516M → $531M (+$15M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 142 → 136 (-6)
9.6% less ownership
Funds ownership: 87.95% → 78.35% (-9.6%)
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
28% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 50
97% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $64.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$115M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$18.5M |
| 3 |
QC
Quadrature Capital
London,
United Kingdom
|
+$11.5M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.2M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$102M |
| 2 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
-$17.3M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$13.2M |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$11.9M |
| 5 |
Two Sigma Investments
New York
|
-$8.48M |
PPH Hedge Fund Activity: Q1 2025 in Review
136 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2025, worth a combined $531M — up 2.9% from $516M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of PPH and 20 opened new positions — a net loss of 5 holders — while 50 trimmed existing stakes and 36 added.
The largest buyer was Fisher Asset Management, opening a new position worth an estimated $115M. The largest seller was Goldman Sachs, cutting an estimated $102M.
- 136 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2025, down from 142 in Q4 2024.
- Funds reported $531M of VanEck Pharmaceutical ETF stock for Q1 2025, up 2.9% quarter-over-quarter.
- 20 funds opened new VanEck Pharmaceutical ETF positions in Q1 2025 and 25 closed out, a net change of -5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2025 was Fisher Asset Management, an estimated $115M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2025 was Goldman Sachs, an estimated $102M sold.
Based on aggregated 13F filings for Q1 2025.